Pipeline
CU105
Pipeline
CU105
CU105
Expanded indications of CU06 to Hereditary Angioedema(HAE)
Sortation | content |
---|---|
CU105 | Expanded indications of CU06 to Hereditary Angioedema(HAE) |
Indication | Hereditary Angioedema(HAE) |
Unmet Needs |
• Approved HAE treatments can minimize the risk of death, but they are not effective in complete healing from the disease. • The new gene therapies seem to provide promising opportunities for the treatment of hereditary angioedema.
• However, there are still many unmet needs, including efficacy, route, and timing of administration
|
Mechanism of Action |
• Treatment of HAE through normalization of endothelial cell barrier |
Efficacy & Safety |
• Prevention of vascular hyperpermeability. • Inhibition of BK-induced HUVEC monolayer disruption. |
Market | 6.5 billion US$ |
Indication
Cause
Incidence, Mortality
Symptoms
Unmet Needs
Mechanism of Action
Pathogenesis of HAE
CU105 Principle of Action
modified from N Engl J Med (2010)
Clinic Rev Allerg Immunol (2021)
Efficacy
In vivo efficacy in BK (Bradykinin) model
Prevention of vascular hyperpermeability: measuring vascular leakage reduction with Evans Blue(dye)
Inhibition of BK-induced HUVEC monolayer disruption
In vivo efficacy in C1-INH deficient model
Prevention of vascular hyperpermeability: measuring vascular leakage reduction with Evans Blue(dye)
Development
In vivo VE-cadherin immunofluorescence staining in BK model
Future Plan
In vivo FITC-dextran permeability assay in BK model
In vivo FITC-dextran permeability assay in BK model